Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone508-683-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.82 billion
Profitability
Miscellaneous
Employees29,000
OptionableOptionable
Boston Scientific (NYSE:BSX) Frequently Asked Questions
What is Boston Scientific's stock symbol?
Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."
How were Boston Scientific's earnings last quarter?
Boston Scientific Co. (NYSE:BSX) posted its quarterly earnings data on Wednesday, February, 6th. The medical equipment provider reported $0.39 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.37 by $0.02. The medical equipment provider earned $2.56 billion during the quarter, compared to the consensus estimate of $2.57 billion. Boston Scientific had a return on equity of 26.80% and a net margin of 17.01%. Boston Scientific's quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.34 earnings per share. View Boston Scientific's Earnings History.
When is Boston Scientific's next earnings date?
What guidance has Boston Scientific issued on next quarter's earnings?
Boston Scientific updated its FY19 earnings guidance on Wednesday, February, 6th. The company provided earnings per share guidance of $1.53-$1.58 for the period, compared to the Thomson Reuters consensus estimate of $1.58. The company issued revenue guidance of $10.51-$10.71 billion, compared to the consensus revenue estimate of $10.64 billion.Boston Scientific also updated its FY 2019 guidance to $1.53-1.58 EPS.
What price target have analysts set for BSX?
25 analysts have issued twelve-month price objectives for Boston Scientific's shares. Their predictions range from $32.00 to $48.00. On average, they anticipate Boston Scientific's share price to reach $40.80 in the next year. This suggests a possible upside of 2.0% from the stock's current price. View Analyst Price Targets for Boston Scientific.
What is the consensus analysts' recommendation for Boston Scientific?
25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 21 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Boston Scientific.
What are Wall Street analysts saying about Boston Scientific stock?
Here are some recent quotes from research analysts about Boston Scientific stock:
- 1. Needham & Company LLC analysts commented, "BSX’s 4Q18 revenue was in line with its 1/8/19 preannouncement while its EPS beat consensus. Management provided 2019 revenue guidance that bracketed consensus and adjusted EPS guidance that was below consensus at its mid-point. BSX’s organic revenue growth slowed to 7% in 3Q18 from 9% in 3Q18 given a more difficult comp. BSX’s operating margin was down 10 bps Y/ Y despite a 70 bps gross margin FX tailwind. Importantly, management indicated that Lotus Edge should be launched in the US in early 2Q19 and that they expect structural heart sales of $700-725M in 2019 which is up ~50% from 2018. Given BSX’s above-peer organic revenue growth, strong product pipeline, and potential for upside to estimates, we reiterate our Strong Buy rating." (2/6/2019)
- 2. According to Zacks Investment Research, "Boston Scientific is suffering from significant cost escalation, which is weighing on its margins. Also, delay in LOTUS relaunch is hampering sales through 2018. Declining worldwide pacemaker sales is also hurting the CRM business. On a brighter note, the company is seeing growth across all business lines and geographies. Boston Scientific received a number of FDA approvals within the Cardiovascular group. This apart, it launched LithoVue within Urology and rolled out the GUIDE XT in Europe. We look forward to the three recent acquisitions- Claret Medical, VENITI and Augmenix. These are expected to strongly contribute to the company’s inorganic growth profile. Boston Scientific’s significant progress related to its LOTUS valve relaunch encourages us. Also, post the suspension of LOTUS valve in Europe, ACURATE TAVR continues to build momentum. Over the past three months, Boston Scientific outperformed its industry." (1/7/2019)
- 3. BTIG Research analysts commented, "Sure Why BSX Buy BSX will acquire BTG plc (BTG-GB, Not Rated) for ~$4B. BTG is in of sales in the U.S. BTG focuses on interventional medicine (oncology and vascular) and also has a pharma division. We are not sure why BSX is trading down ~3%, which is about $1B. This makes little sense to us on a $4B deal. We see the interventional space as a high growth area and oncology/vascular fit within BSX salesforces. BSX has used capital well buying Asthmatx recently. Between this track record and consistently hitting targets, we thought BSX would have leeway with investors to make purchases. BTG’s business OUS, we see this deal as similar to AMS, which has been hugely successful for BSX as it has expanded sales OUS. We feel this deal should benefit BSX’s interventional business like AMMD added growth to urology." (11/21/2018)
Has Boston Scientific been receiving favorable news coverage?
Headlines about BSX stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Boston Scientific earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Boston Scientific's key competitors?
Some companies that are related to Boston Scientific include 3M (MMM), Stryker (SYK), Becton Dickinson and (BDX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Penumbra (PEN), ICU Medical (ICUI), Insulet (PODD), Novocure (NVCR) and Globus Medical (GMED).
Who are Boston Scientific's key executives?
Boston Scientific's management team includes the folowing people:
- Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 54)
- Mr. Daniel J. Brennan, Exec. VP & CFO (Age 53)
- Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 55)
- Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 46)
- Mr. Edward F. Mackey, Exec. VP of Operations (Age 56)
Who are Boston Scientific's major shareholders?
Boston Scientific's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.42%), Bollard Group LLC (2.43%), Geode Capital Management LLC (1.23%), Northern Trust Corp (1.12%), Bank of New York Mellon Corp (1.09%) and Oregon Public Employees Retirement Fund (0.87%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun, Wendy Carruthers, Xin Warren Wang and Yoshiaki Fujimori. View Institutional Ownership Trends for Boston Scientific.
Which major investors are selling Boston Scientific stock?
BSX stock was sold by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, Eaton Vance Management, Bank of New York Mellon Corp, First Quadrant L P CA, Diamond Hill Capital Management Inc., Lord Abbett & CO. LLC, Epoch Investment Partners Inc. and Deroy & Devereaux Private Investment Counsel Inc.. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Xin Warren Wang and Yoshiaki Fujimori. View Insider Buying and Selling for Boston Scientific.
Which major investors are buying Boston Scientific stock?
BSX stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Massachusetts Financial Services Co. MA, BlackRock Inc., Geode Capital Management LLC, Polar Capital LLP, 1832 Asset Management L.P., Amundi Pioneer Asset Management Inc. and California Public Employees Retirement System. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific.
How do I buy shares of Boston Scientific?
Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Boston Scientific's stock price today?
One share of BSX stock can currently be purchased for approximately $40.01.
How big of a company is Boston Scientific?
Boston Scientific has a market capitalization of $55.37 billion and generates $9.82 billion in revenue each year. The medical equipment provider earns $1.67 billion in net income (profit) each year or $1.47 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.
What is Boston Scientific's official website?
How can I contact Boston Scientific?
Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]
MarketBeat Community Rating for Boston Scientific (NYSE BSX)
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
